Patent ID: 8470776

Claim:
A method for the treatment of ovarian, endometrial, cervical, uterine, prostate, bladder, liver, stomach, pancreatic, breast, colon, brain, lung or skin cancer, multiple myeloma, lymphoma or leukemia, comprising administering to a patient in need thereof a compound of the formula (I) or (IV): C1-B1-A-B2-C2 (I) C1-B1-A (IV), wherein A is a disorazole moiety according to formula (III) wherein Ri o , Rj o , Rk p , Rm p , R28, R30, R31, R32R33, R34, R35, R36, R38, R40, R41, R42, R43, and R44 are hydrogen; R 1 p and Rn p together form a double bond or are independently selected from the group consisting of hydrogen and alkoxyl; R27 and R29 together form a double bond or an epoxide; R37 and R39 together form a double bond or an epoxide; R25 and R26 are independently from each other selected from the group consisting of: alkyl which is optionally substituted in the alkyl group by 1, 2 or 3 substituents independently from each other selected from the group consisting of alkyl, cycloalkyl, cycloalkyl-alkyl, aryl, heteroaryl, aryl-alkyl, heteroaryl-alkyl, heterocyclyl, heterocyclyl-alkyl, alkylsulfonyl, arylsulfonyl, aryl-alkylsulfonyl, halogen, —F, —Cl, —Br, —I, —N 3 , ═O, ═S, ═S(O) 2 , hydroxyl, carbonyl, acetyl, carboxyl, carboxylester, amide, carbonate, carbamate, alpha-amino acid residues, beta-amino acid residues, alkoxyl, amino, imino, hydroxylamino, mono-alkylamino, di-alkylamino, hydrazinyl, cyano, alkyl-cyano, sulfhydryl, disulfidylalkyl and alkyl-sulfidyl; B1 and B2 are independently from each other selected from the group consisting of dicarbonic acid residue linker, succinyl and glutaryl; C1 and C2 are independently from each other selected from the group consisting of LHRH, [D-Lys 6 ]-LHRH, somatostatin, and a somatostatin analogue; o is 1 or 2; and p is 1 or 2.